| Rank |
Title |
Year |
PubWeight™‹?› |
|
1
|
What Has 30 Years of HIV Vaccine Research Taught Us?
|
2013
|
1.06
|
|
2
|
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.
|
2014
|
1.04
|
|
3
|
Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.
|
2014
|
1.01
|
|
4
|
Vaccine Adjuvants: from 1920 to 2015 and Beyond.
|
2015
|
0.99
|
|
5
|
Peptide Vaccine: Progress and Challenges.
|
2014
|
0.94
|
|
6
|
Developments in Viral Vector-Based Vaccines.
|
2014
|
0.94
|
|
7
|
Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines.
|
2015
|
0.93
|
|
8
|
Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation.
|
2013
|
0.93
|
|
9
|
M2e-Based Universal Influenza A Vaccines.
|
2015
|
0.93
|
|
10
|
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy.
|
2015
|
0.91
|
|
11
|
A Multidisciplinary Research Agenda for Understanding Vaccine-Related Decisions.
|
2013
|
0.90
|
|
12
|
Therapeutic Vaccine Strategies against Human Papillomavirus.
|
2014
|
0.89
|
|
13
|
Vector Design for Improved DNA Vaccine Efficacy, Safety and Production.
|
2013
|
0.88
|
|
14
|
CpG Oligonucleotides as Cancer Vaccine Adjuvants.
|
2015
|
0.87
|
|
15
|
Whole Tumor Antigen Vaccines: Where Are We?
|
2015
|
0.87
|
|
16
|
Acceptability of Condoms, Circumcision and PrEP among Young Black Men Who Have Sex with Men: A Descriptive Study Based on Effectiveness and Cost.
|
2014
|
0.86
|
|
17
|
Tumor-Associated Glycans and Immune Surveillance.
|
2013
|
0.86
|
|
18
|
Recent Developments in Preclinical DNA Vaccination.
|
2014
|
0.85
|
|
19
|
Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery.
|
2015
|
0.85
|
|
20
|
A Systematic Review of Recent Advances in Equine Influenza Vaccination.
|
2014
|
0.85
|
|
21
|
Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators.
|
2014
|
0.84
|
|
22
|
The Potential Impact of Preventive HIV Vaccines in China: Results and Benefits of a Multi-Province Modeling Collaboration.
|
2015
|
0.84
|
|
23
|
Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands.
|
2014
|
0.84
|
|
24
|
Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines.
|
2015
|
0.84
|
|
25
|
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity.
|
2015
|
0.83
|
|
26
|
Optimal Use of Vaccines for Control of Influenza A Virus in Swine.
|
2015
|
0.83
|
|
27
|
Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens.
|
2013
|
0.83
|
|
28
|
Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention.
|
2014
|
0.83
|
|
29
|
Beliefs and Opinions of Health Care Workers and Students Regarding Influenza and Influenza Vaccination in Tuscany, Central Italy.
|
2015
|
0.83
|
|
30
|
Are Recent Medical Graduates More Skeptical of Vaccines?
|
2013
|
0.83
|
|
31
|
Sustaining Vaccine Confidence in the 21st Century.
|
2013
|
0.83
|
|
32
|
HSP70 promoter-driven activation of gene expression for immunotherapy using gold nanorods and near infrared light.
|
2014
|
0.83
|
|
33
|
Emerging Influenza Strains in the Last Two Decades: A Threat of a New Pandemic?
|
2015
|
0.83
|
|
34
|
Leptin-Induced JAK/STAT Signaling and Cancer Growth.
|
2016
|
0.82
|
|
35
|
Gavi HPV Programs: Application to Implementation.
|
2015
|
0.82
|
|
36
|
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting.
|
2016
|
0.82
|
|
37
|
Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination.
|
2013
|
0.82
|
|
38
|
Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies.
|
2014
|
0.82
|
|
39
|
Gas Vesicle Nanoparticles for Antigen Display.
|
2015
|
0.82
|
|
40
|
Schistosome Vaccine Adjuvants in Preclinical and Clinical Research.
|
2014
|
0.82
|
|
41
|
A Recombinant Raccoon Poxvirus Vaccine Expressing both Yersinia pestis F1 and Truncated V Antigens Protects Animals against Lethal Plague.
|
2014
|
0.81
|
|
42
|
Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques.
|
2013
|
0.81
|
|
43
|
Chemokines as Cancer Vaccine Adjuvants.
|
2013
|
0.81
|
|
44
|
Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity.
|
2015
|
0.81
|
|
45
|
Cholera Toxin Subunit B as Adjuvant--An Accelerator in Protective Immunity and a Break in Autoimmunity.
|
2015
|
0.81
|
|
46
|
Change in Hepatitis A Seroprevalence among U.S. Children and Adolescents: Results from the National Health and Nutrition Examination Survey 2003-2006 and 2007-2010.
|
2013
|
0.81
|
|
47
|
Nonclinical Development of BCG Replacement Vaccine Candidates.
|
2013
|
0.81
|
|
48
|
Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head.
|
2015
|
0.81
|
|
49
|
HIV DNA Vaccine: Stepwise Improvements Make a Difference.
|
2014
|
0.81
|
|
50
|
Co-Administration of Molecular Adjuvants Expressing NF-Kappa B Subunit p65/RelA or Type-1 Transactivator T-bet Enhance Antigen Specific DNA Vaccine-Induced Immunity.
|
2014
|
0.80
|